GlassScriptPhysician profile
Tracey J Grappe
NPI 1225077282
$5,350.52
in general payments reported to CMS, 2019-2025
37 companies · $993 in 2025
The $993 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,238 · 2022: $1,236 · 2023: $996 · 2024: $887 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $737.36 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $504.62 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.93 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $387.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $384.70 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $366.12 | 2021-2023 | |
| Pfizer INC. | $318.51 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $259.51 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $184.38 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $167.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.27 | 2021-2023 | Trintellix |
| Dexcom, INC. | $131.22 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $120.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $118.19 | 2021-2022 | |
| Amgen INC. | $106.81 | 2021-2025 | Repatha, Otezla, Repatha |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Grappe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.